非酒精性脂肪性肝炎的药物治疗:现状与新兴疗法
非酒精性脂肪性肝病(NAFLD)已成为全球主要慢性肝病之一,其进展型非酒精性脂肪性肝炎(NASH)患者多系统疾病和死亡风险显著增加,但目前尚无获批药物。本文综述了针对代谢通路、炎症级联和纤维化机制的在研药物,指出IIa期化合物在组织病理学方面显示有希望的结果,而后期阶段药物在减少肝脂肪变、坏死性炎症和纤维化方面效果较温和。
要点
- NAFLD已成为全球主要慢性肝病之一,NASH患者多系统疾病和死亡风险显著增加。
- 目前尚无获批的NASH药物治疗方案,存在重要未满足需求。
- 在研药物靶向代谢通路、炎症级联和纤维化机制,IIa期化合物显示有希望的组织病理学益处。
核心结论
- 若在异质性队列中确立长期安全性和有效性,这些药物可能有助于降低这一快速增长患者群体的潜在疾病和死亡风险。
研究设计与样本
- 综述,聚焦NAFLD和NASH的药物治疗现状与新兴疗法。
主要发现
- IIa期化合物在组织病理学多个方面显示出有希望的潜在益处。
- 后期开发阶段药物在减少肝脂肪变、坏死性炎症和纤维化方面显示出较温和的结果。
局限性
- NAFLD和NASH的药物治疗开发受到临床试验入组困难和临床试验设计复杂性的阻碍。
- 目前尚无获批的NASH药物治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-alcoholic fatty liver disease (NAFLD) has become one of the most prominent forms of chronic liver disease worldwide, reflecting the epidemic of global obesity. Those with the progressive variant of NAFLD, non-alcoholic steatohepatitis (NASH), are at significantly increased risk of multisystem morbidity and mortality. However, there are currently no approved pharmacologic therapies for NASH. Given the disease burden, there is an important unmet need for pharmacologic treatment options for this patient population. The underlying pathophysiologic mechanisms that contribute to the development and progression of NAFLD and NASH are complex and reflected by the myriad of therapies, with different targets, currently under investigation. In broad strokes, drug development has focused on modulation of metabolic pathways, inflammatory cascades, and/or mechanisms impacting fibrosis. Although much progress has been made in enhancing our understanding of NAFLD pathogenesis, development of pharmacologic treatments has been hindered by challenges in clinical trial enrollment and complexities in clinical trial design. The compounds in phase IIa have provided promising results in terms of potential benefits on various aspects of histopathology. Agents in later stages of development have shown fairly modest results in terms of reduction of hepatic steatosis, necroinflammation and fibrosis. If longer term safety and efficacy are established among heterogeneous cohorts, these medications may help mitigate potential morbidity and mortality for this burgeoning patient population.
引用
- Konerman MA, Jones JC, Harrison SA, et al. Pharmacotherapy for NASH: Current and emerging. J Hepatol. 2017. PMID: 29122694. doi:10.1016/j.jhep.2017.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。